Cargando…
Rapidly produced SAM(®) vaccine against H7N9 influenza is immunogenic in mice
The timing of vaccine availability is essential for an effective response to pandemic influenza. In 2009, vaccine became available after the disease peak, and this has motivated the development of next generation vaccine technologies for more rapid responses. The SAM(®) vaccine platform, now in pre-...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3821287/ https://www.ncbi.nlm.nih.gov/pubmed/26038486 http://dx.doi.org/10.1038/emi.2013.54 |
_version_ | 1782290275982376960 |
---|---|
author | Hekele, Armin Bertholet, Sylvie Archer, Jacob Gibson, Daniel G Palladino, Giuseppe Brito, Luis A Otten, Gillis R Brazzoli, Michela Buccato, Scilla Bonci, Alessandra Casini, Daniele Maione, Domenico Qi, Zhi-Qing Gill, John E Caiazza, Nicky C Urano, Jun Hubby, Bolyn Gao, George F Shu, Yuelong De Gregorio, Ennio Mandl, Christian W Mason, Peter W Settembre, Ethan C Ulmer, Jeffrey B Craig Venter, J Dormitzer, Philip R Rappuoli, Rino Geall, Andrew J |
author_facet | Hekele, Armin Bertholet, Sylvie Archer, Jacob Gibson, Daniel G Palladino, Giuseppe Brito, Luis A Otten, Gillis R Brazzoli, Michela Buccato, Scilla Bonci, Alessandra Casini, Daniele Maione, Domenico Qi, Zhi-Qing Gill, John E Caiazza, Nicky C Urano, Jun Hubby, Bolyn Gao, George F Shu, Yuelong De Gregorio, Ennio Mandl, Christian W Mason, Peter W Settembre, Ethan C Ulmer, Jeffrey B Craig Venter, J Dormitzer, Philip R Rappuoli, Rino Geall, Andrew J |
author_sort | Hekele, Armin |
collection | PubMed |
description | The timing of vaccine availability is essential for an effective response to pandemic influenza. In 2009, vaccine became available after the disease peak, and this has motivated the development of next generation vaccine technologies for more rapid responses. The SAM(®) vaccine platform, now in pre-clinical development, is based on a synthetic, self-amplifying mRNA, delivered by a synthetic lipid nanoparticle (LNP). When used to express seasonal influenza hemagglutinin (HA), a SAM vaccine elicited potent immune responses, comparable to those elicited by a licensed influenza subunit vaccine preparation. When the sequences coding for the HA and neuraminidase (NA) genes from the H7N9 influenza outbreak in China were posted on a web-based data sharing system, the combination of rapid and accurate cell-free gene synthesis and SAM vaccine technology allowed the generation of a vaccine candidate in 8 days. Two weeks after the first immunization, mice had measurable hemagglutinin inhibition (HI) and neutralizing antibody titers against the new virus. Two weeks after the second immunization, all mice had HI titers considered protective. If the SAM vaccine platform proves safe, potent, well tolerated and effective in humans, fully synthetic vaccine technologies could provide unparalleled speed of response to stem the initial wave of influenza outbreaks, allowing first availability of a vaccine candidate days after the discovery of a new virus. |
format | Online Article Text |
id | pubmed-3821287 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-38212872013-11-09 Rapidly produced SAM(®) vaccine against H7N9 influenza is immunogenic in mice Hekele, Armin Bertholet, Sylvie Archer, Jacob Gibson, Daniel G Palladino, Giuseppe Brito, Luis A Otten, Gillis R Brazzoli, Michela Buccato, Scilla Bonci, Alessandra Casini, Daniele Maione, Domenico Qi, Zhi-Qing Gill, John E Caiazza, Nicky C Urano, Jun Hubby, Bolyn Gao, George F Shu, Yuelong De Gregorio, Ennio Mandl, Christian W Mason, Peter W Settembre, Ethan C Ulmer, Jeffrey B Craig Venter, J Dormitzer, Philip R Rappuoli, Rino Geall, Andrew J Emerg Microbes Infect Original Article The timing of vaccine availability is essential for an effective response to pandemic influenza. In 2009, vaccine became available after the disease peak, and this has motivated the development of next generation vaccine technologies for more rapid responses. The SAM(®) vaccine platform, now in pre-clinical development, is based on a synthetic, self-amplifying mRNA, delivered by a synthetic lipid nanoparticle (LNP). When used to express seasonal influenza hemagglutinin (HA), a SAM vaccine elicited potent immune responses, comparable to those elicited by a licensed influenza subunit vaccine preparation. When the sequences coding for the HA and neuraminidase (NA) genes from the H7N9 influenza outbreak in China were posted on a web-based data sharing system, the combination of rapid and accurate cell-free gene synthesis and SAM vaccine technology allowed the generation of a vaccine candidate in 8 days. Two weeks after the first immunization, mice had measurable hemagglutinin inhibition (HI) and neutralizing antibody titers against the new virus. Two weeks after the second immunization, all mice had HI titers considered protective. If the SAM vaccine platform proves safe, potent, well tolerated and effective in humans, fully synthetic vaccine technologies could provide unparalleled speed of response to stem the initial wave of influenza outbreaks, allowing first availability of a vaccine candidate days after the discovery of a new virus. Nature Publishing Group 2013-08 2013-08-14 /pmc/articles/PMC3821287/ /pubmed/26038486 http://dx.doi.org/10.1038/emi.2013.54 Text en Copyright © 2013 Shanghai Shangyixun Cultural Communication Co., Ltd http://creativecommons.org/licenses/by-nc-nd/3.0/ This work is licensed under the Creative Commons Attribution-NonCommercial-No Derivative Works 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/ |
spellingShingle | Original Article Hekele, Armin Bertholet, Sylvie Archer, Jacob Gibson, Daniel G Palladino, Giuseppe Brito, Luis A Otten, Gillis R Brazzoli, Michela Buccato, Scilla Bonci, Alessandra Casini, Daniele Maione, Domenico Qi, Zhi-Qing Gill, John E Caiazza, Nicky C Urano, Jun Hubby, Bolyn Gao, George F Shu, Yuelong De Gregorio, Ennio Mandl, Christian W Mason, Peter W Settembre, Ethan C Ulmer, Jeffrey B Craig Venter, J Dormitzer, Philip R Rappuoli, Rino Geall, Andrew J Rapidly produced SAM(®) vaccine against H7N9 influenza is immunogenic in mice |
title | Rapidly produced SAM(®) vaccine against H7N9 influenza is immunogenic in mice |
title_full | Rapidly produced SAM(®) vaccine against H7N9 influenza is immunogenic in mice |
title_fullStr | Rapidly produced SAM(®) vaccine against H7N9 influenza is immunogenic in mice |
title_full_unstemmed | Rapidly produced SAM(®) vaccine against H7N9 influenza is immunogenic in mice |
title_short | Rapidly produced SAM(®) vaccine against H7N9 influenza is immunogenic in mice |
title_sort | rapidly produced sam(®) vaccine against h7n9 influenza is immunogenic in mice |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3821287/ https://www.ncbi.nlm.nih.gov/pubmed/26038486 http://dx.doi.org/10.1038/emi.2013.54 |
work_keys_str_mv | AT hekelearmin rapidlyproducedsamvaccineagainsth7n9influenzaisimmunogenicinmice AT bertholetsylvie rapidlyproducedsamvaccineagainsth7n9influenzaisimmunogenicinmice AT archerjacob rapidlyproducedsamvaccineagainsth7n9influenzaisimmunogenicinmice AT gibsondanielg rapidlyproducedsamvaccineagainsth7n9influenzaisimmunogenicinmice AT palladinogiuseppe rapidlyproducedsamvaccineagainsth7n9influenzaisimmunogenicinmice AT britoluisa rapidlyproducedsamvaccineagainsth7n9influenzaisimmunogenicinmice AT ottengillisr rapidlyproducedsamvaccineagainsth7n9influenzaisimmunogenicinmice AT brazzolimichela rapidlyproducedsamvaccineagainsth7n9influenzaisimmunogenicinmice AT buccatoscilla rapidlyproducedsamvaccineagainsth7n9influenzaisimmunogenicinmice AT boncialessandra rapidlyproducedsamvaccineagainsth7n9influenzaisimmunogenicinmice AT casinidaniele rapidlyproducedsamvaccineagainsth7n9influenzaisimmunogenicinmice AT maionedomenico rapidlyproducedsamvaccineagainsth7n9influenzaisimmunogenicinmice AT qizhiqing rapidlyproducedsamvaccineagainsth7n9influenzaisimmunogenicinmice AT gilljohne rapidlyproducedsamvaccineagainsth7n9influenzaisimmunogenicinmice AT caiazzanickyc rapidlyproducedsamvaccineagainsth7n9influenzaisimmunogenicinmice AT uranojun rapidlyproducedsamvaccineagainsth7n9influenzaisimmunogenicinmice AT hubbybolyn rapidlyproducedsamvaccineagainsth7n9influenzaisimmunogenicinmice AT gaogeorgef rapidlyproducedsamvaccineagainsth7n9influenzaisimmunogenicinmice AT shuyuelong rapidlyproducedsamvaccineagainsth7n9influenzaisimmunogenicinmice AT degregorioennio rapidlyproducedsamvaccineagainsth7n9influenzaisimmunogenicinmice AT mandlchristianw rapidlyproducedsamvaccineagainsth7n9influenzaisimmunogenicinmice AT masonpeterw rapidlyproducedsamvaccineagainsth7n9influenzaisimmunogenicinmice AT settembreethanc rapidlyproducedsamvaccineagainsth7n9influenzaisimmunogenicinmice AT ulmerjeffreyb rapidlyproducedsamvaccineagainsth7n9influenzaisimmunogenicinmice AT craigventerj rapidlyproducedsamvaccineagainsth7n9influenzaisimmunogenicinmice AT dormitzerphilipr rapidlyproducedsamvaccineagainsth7n9influenzaisimmunogenicinmice AT rappuolirino rapidlyproducedsamvaccineagainsth7n9influenzaisimmunogenicinmice AT geallandrewj rapidlyproducedsamvaccineagainsth7n9influenzaisimmunogenicinmice |